Information Provided By: 
Fly News Breaks for March 30, 2016
ACAD
Mar 30, 2016 | 07:07 EDT
Piper Jaffray analyst Charles Duncan raised his price target for ACADIA Pharmaceuticals to $44 saying regulatory risk is "substantially reduced" for Nuplazid following yesterday's FDA panel vote. The analyst says he has renewed conviction in the drug's potential for Parkinson's disease psychosis commercialization and as an uncommon, wholly-owned and long-lived neuropsych asset. He keeps an Overweight rating on shares of ACADIA.
News For ACAD From the Last 2 Days
